Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Three Months Ended June 30, 2026" Please note that the title may not be exact, as the provided text is a financial report and may not contain a specific title. However, based on the content, I inferred the title to be a quarterly report for the three months ended June 30, 2026.
The financial report presents the financial statements of the company for the quarter ended June 30, 2026, and the year ended December 31, 2025. The company reported net income of $X million for the quarter and $Y million for the year. Total revenue increased by Z% to $W million for the quarter and by X% to $V million for the year. The company’s cash and cash equivalents decreased by $X million to $Y million as of June 30, 2026. The company’s total assets increased by $Z million to $W million as of June 30, 2026, while total liabilities decreased by $X million to $Y million. The company’s common stock outstanding decreased by X shares to Y shares as of June 30, 2026. The company’s preferred stock outstanding remained unchanged at Z shares as of June 30, 2026.
Overview of Vycor Medical, Inc.’s Financial Performance
Vycor Medical, Inc. is a medical device company that operates two distinct business units - Vycor Medical and NovaVision. The company’s financial performance for the three and six months ended June 30, 2026 is summarized below:
Revenue and Gross Margin:
| Metric | Three Months Ended June 30 | Six Months Ended June 30 | ||
|---|---|---|---|---|
| 2026 | 2025 | % Change | 2026 | |
| Vycor Medical Revenue | $401,224 | $481,788 | -17% | $841,665 |
| NovaVision Revenue | $17,040 | $14,565 | 17% | $35,139 |
| Total Revenue | $418,264 | $496,353 | -16% | $876,804 |
| Vycor Medical Gross Profit | $327,225 | $401,783 | -19% | $686,265 |
| NovaVision Gross Profit | $17,220 | $13,488 | 28% | $33,333 |
| Total Gross Profit | $344,445 | $415,271 | -17% | $719,598 |
| Vycor Medical Gross Margin | 82% | 83% | -1% | 82% |
| NovaVision Gross Margin | 101% | 93% | 8% | 95% |
| Total Gross Margin | 82% | 84% | -2% | 82% |
The key points are:
- Vycor Medical revenue decreased by 17% and 7% in the three and six month periods respectively, primarily due to lower international sales. Gross margin remained relatively stable.
- NovaVision revenue increased by 17% and 8% in the three and six month periods respectively, with improved gross margins.
- Overall, total revenue and gross profit declined by 16% and 17% in the three month period, and 6% and 7% in the six month period.
Expenses:
- Research & Development expenses were $0 in 2026 compared to $4,201 and $9,963 in the three and six month periods of 2025.
- Selling, General and Administrative (SG&A) expenses decreased by $22,332 and $57,665 in the three and six month periods respectively, primarily due to lower stock-based compensation and sales commissions.
Liquidity:
- The company had a working capital deficit of $4,294,543 as of June 30, 2026, including $3,800,538 in related party liabilities.
- Cash provided by operating activities was $94,579 in the six months ended June 30, 2026, an increase of $74,855 compared to the prior year period.
- The company believes it may not have sufficient cash to meet its needs through August 2027 without additional financing, and its largest shareholder has provided working capital funding on an as-needed basis.
Overall, Vycor Medical’s financial performance declined in the first half of 2026 compared to the prior year, with lower revenue and profitability. The company faces liquidity challenges and uncertainty about its ability to continue as a going concern. Management is executing a plan to reduce operating losses, but additional financing may be required.
